# Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

> **NCT02878603** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 104 (actual)

## Conditions studied

- Acquired Thrombotic Thrombocytopenic Purpura

## Interventions

- **BIOLOGICAL:** Caplacizumab
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT02878603
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-06
- **Primary completion:** 2020-10-23
- **Final completion:** 2020-10-23
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02878603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02878603, "Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02878603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*